that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 16, 1997.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. CCB Financial Corporation, Durham, North Carolina; to acquire American Federal Bank, F.S.B., Greenville, South Carolina, and thereby engage in engaging in mortgage lending; acting as agent in the sale of certain credit related insurance; operating a savings association; and providing securities brokerage services, pursuant to §§ 225.25(b)(1)(iii), (8)(i), (9), and (15) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, April 16, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–10290 Filed 4–21–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the ''Schedule of Certified Interest Rates with Range of Maturities.'' This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 13½ percent for the quarter ended March 31, 1997. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: April 15, 1997.

Shirl A. Ruffin,

Acting Deputy Assistant Secretary, Finance.

[FR Doc. 97–10384 Filed 4–21–97; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY–6–97]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639–7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

Proposed Project

1. State-Based Evaluation of Trends and Risk Factors in Morbidity and Mortality from Sickle Cell Disease After Newborn Screening—New—Children with sickle cell disease are at increased risk for mortality and morbidity, especially in the first three years of life. The need for early diagnosis and preventive medical intervention is the rationale for newborn hemoglobinopathy screening programs, now operating in more than 40 states. Although clinical trials have clearly demonstrated the efficacy of early medical intervention, more information is needed regarding the actual utilization of available therapies and preventive measures in large populations, health statuses of children identified by newborn screening programs, and risk factors for adverse health outcomes. Potential risk factors include extent of medical care follow-up, location of treatment, the use of penicillin prophylaxis, immunization patterns, as well as parental social, demographic and educational factors. In FY 1995, CDC awarded $150,000 to three state health departments to assist in their efforts to ascertain health status and risk factors for young children with sickle cell disease. States will be using these funds to obtain information about individual children through structured questionnaires directed toward their parents and physicians. The total annual burden hours are 840.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Parents	840	1	.5	420
Physicians	840	1	.5	420

Wilma G. Johnson,

Acting Associate Director for Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–10312 Filed 4–21–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0157]

Japan Vilene Co., Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Japan Vilene Co., Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2-propenoic acid, polymer with 2-ethyl-2-(((1-oxo-2-propenyl)oxy)methyl)-1,3-propanediyl di-2-propenoate and sodium 2-propenoate (CAS Reg. No. 76774–25–9) as a fluid absorbent material intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by May 22, 1997.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3095.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 7B4537) has been filed by Japan Vilene Co., Ltd., c/o Center for Regulatory Services, 2347 Paddock Lane, Reston, VA 20191. The petition proposes to amend the food additive regulations to provide for the safe use of 2-propenoic acid, polymer with 2-ethyl-2-(((1-oxo-2-propenyl)oxy)methyl)-1,3-propanediyl di-2-propenoate and sodium 2-propenoate (CAS Reg. No. 76774–25–9) as a fluid absorbent material intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before May 22, 1997, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: April 1, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–10415 Filed 4–21–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94D–0422]

Guidance for Industry: Current Good Manufacturing Practices for Positron Emission Tomographic (PET) Drug Products; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ''Guidance for Industry: Current Good Manufacturing Practices for Positron Emission Tomographic (PET) Drug Products'' prepared by FDA's Center for Drug Evaluation and Research (CDER). The guidance is intended to assist persons involved in the production of PET radiopharmaceutical drug products in achieving compliance with FDA's current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.

DATES: Persons may submit written comments on the guidance at any time.

ADDRESSES: Submit written requests for single copies of the guidance entitled ''Guidance for Industry: Current Good Manufacturing Practices for Positron Emission Tomographic (PET) Drug Products'' to the Drug Information Branch (HFD–210), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Send one self-addressed adhesive label to assist that office in processing your requests. An electronic version of this guidance is available via Internet using the World Wide Web (WWW). To connect to the CDER home page, type ''http://www.fda.gov/cder'' and go to the ''Regulatory Guidance'' section. Submit written comments on the guidance to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the guidance and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Robert K. Leedham, Center for Drug Evaluation and Research (HFD–343), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 301–594–1026.

SUPPLEMENTARY INFORMATION: FDA is announcing the availability of a guidance entitled ''Guidance for Industry: Current Good Manufacturing Practices for Positron Emission Tomographic (PET) Drug Products.'' PET is a medical imaging modality used to assess the body's biochemical processes. Radionuclides are manufactured into PET radiopharmaceutical drug products that are administered to patients for medical imaging. The images of the body's biochemical processes are then evaluated, generally for diagnostic purposes.

In the **Federal Register** of February 27, 1995 (60 FR 10593), FDA announced the availability of its ''Draft Guideline on the Manufacture of Positron Emission Tomographic (PET) Drug Products.'' The notice gave interested persons an opportunity to submit comments by May 30, 1995. FDA received comments from more than 20 persons. The final PET CGMP guidance